Verteporfin

證據等級: L5

預測適應症: 1 個

Verteporfin: From Photodynamic Therapy for Neovascular AMD to Mitochondrial Oxidative Phosphorylation Disorder

One-Sentence Summary

Verteporfin (DrugBank DB00460) is a benzoporphyrin-derivative photosensitizer established in photodynamic therapy for choroidal neovascularization. The TxGNN model predicts it may be relevant to mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal with no independent evidence yet.

Quick Overview

Item	Content
Original Indication	Photodynamic therapy for choroidal neovascularization (e.g. age-related macular degeneration) — based on established pharmacological knowledge; not present in this evidence pack, which has no `original_indications` data
Predicted New Indication	Mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies
TxGNN Prediction Score	99.49% (global rank 5558)
Evidence Level	L5
Taiwan Market Status	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (flagged as data gap DG002, High severity). Based on established pharmacological knowledge, verteporfin accumulates preferentially in proliferating/neovascular tissue and, once activated by non-thermal red light, generates reactive oxygen species that selectively damage the target endothelium — its established clinical role is ophthalmic photodynamic therapy.

The predicted indication — a nuclear-DNA-related mitochondrial OXPHOS disorder — has no obvious mechanistic overlap with this photoactivation pathway. TxGNN's score reflects a knowledge-graph association rather than a validated pharmacological link, and the pack's own repurposing_rationale fields (mechanistic_link, similarity_to_original) are both marked pending, meaning expert mechanistic review has not yet been done.

Because the original indication itself is also missing from this evidence pack (empty original_indications), the comparison between original and predicted indications cannot be substantiated from the data provided. This prediction should be treated as hypothesis-generating only, pending mechanistic review and confirmation of TFDA/regulatory labeling (data gap DG001, Blocking severity).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Verteporfin is not marketed in Taiwan (market status: 未上市), with 0 active authorizations recorded — no license table available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This is an L5, model-prediction-only signal with no clinical trials, no literature, and no mechanistic analysis completed, combined with a Blocking data gap on TFDA labeling. There is currently insufficient evidence to proceed even under guardrails.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — Blocking gap DG001
Verified mechanism of action (DrugBank/primary literature) — High gap DG002
Confirmed original indication data (currently empty in this pack)
Completion of mechanistic_link and similarity_to_original rationale analysis
Ongoing monitoring for emerging clinical trials or literature on this indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.